Liraglutide 3.0 Investigated for Visceral Adiposity Reduction in High-Risk Overweight Adults
Impact of Liraglutide 3.0 on Body Fat Distribution
Abstract
Liraglutide 3.0 is being investigated for reducing visceral adiposity via MRI in overweight/obese adults at high cardiovascular disease risk.